Roche signs up for $774M development pact

Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront payment from Roche, with close to $700 million in milestones that will be split 60/40 between ThromboGenics and BioInvent.

Roche is clearly impressed with the potential of TB-403, an antibody which works by cutting off blood flow to tumors. The therapy has already been tested in one early-stage study and Roche will pick up responsibility for financing further research. Roche gets worldwide marketing rights to the antibody with the two biotechs retaining co-marketing rights in Belgium, the Netherlands, Luxembourg and the Baltic and Nordic Regions.

This deal represents a significant milestone in ThromboGenics' development as a company," said ThromboGenics CEO Désiré Collen. "It also reflects TB-403's potential as a promising treatment for cancer, and is a testament to the hard work and high quality science on which ThromboGenics' business is based."


- read the press release
- check out the AP report

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.